FDA Review Of CLIA Lab Test QC Instructions Not Needed – CMS Quality Rule
This article was originally published in The Gray Sheet
Executive Summary
Manufacturer-provided quality control instructions for clinical lab assays will not be subject to FDA review, the Centers for Medicare & Medicaid Services declares in its Jan. 24 final rule on CLIA quality systems
You may also be interested in...
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Abbott Labs is urging CDRH to clarify that its April 1draft guidance on multiplex tests for heritable markers, mutations and expression patterns applies only to device submissions
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Abbott Labs is urging CDRH to clarify that its April 1draft guidance on multiplex tests for heritable markers, mutations and expression patterns applies only to device submissions
Confusion Over CLIA QC For POCTs Persists; CMS Guidance Forthcoming
CMS will provide guidance for laboratories and the agency's regional offices to clarify implementation procedures detailed in the CLIA Quality Control (QC) final rule in the next several weeks